
Stereotaxis Inc (STXS) Stock Forecast & Price Target
Stereotaxis Inc (STXS) Analyst Ratings
Bulls say
Stereotaxis Inc. projects substantial growth in key revenue streams, with forecasts for FY26E indicating a 24% increase in systems revenue to $43M, a 20% rise in disposables to $12M, and a 25% increase in recurring revenue to $31M, driven by the adoption of new systems and continued utilization of catheters. In its most recent quarter, the company demonstrated strong financial performance, reporting a 95% year-over-year revenue increase to $8.8M and robust recurring revenue growth of 35% to $5.8M, underscoring the impact of new product launches such as the Map-iT and MAGiC ablation catheters. Furthermore, Stereotaxis has achieved significant regulatory milestones, positioning itself for enhanced market leverage with the anticipated launches of next-generation robotic and mapping catheters, thus supporting its outlook for double-digit revenue growth leading into FY26.
Bears say
Stereotaxis Inc. is facing a challenging financial landscape, highlighted by a net loss of $3.8 million and a cash runway of only two years, indicating potential liquidity issues unless additional financing is secured. Operating expenses have shown a slight decrease; however, ongoing supply challenges, delays in new product approvals, and reimbursement rate reductions pose significant risks to revenue generation and profitability. Additionally, the competitive environment from manual and alternative robotic systems further complicates the company’s ability to capture market share and achieve its financial targets.
This aggregate rating is based on analysts' research of Stereotaxis Inc and is not a guaranteed prediction by Public.com or investment advice.
Stereotaxis Inc (STXS) Analyst Forecast & Price Prediction
Start investing in Stereotaxis Inc (STXS)
Order type
Buy in
Order amount
Est. shares
0 shares